hydroxyphenstatin | 290347-52-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: hydroxyphenstatin
• 英文别名: (2',3'-dihydroxy-4'-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone；(2,3-dihydroxy-4-methoxyphenyl)-(3,4,5-trimethoxyphenyl)methanone
• CAS: 290347-52-3
• 化学式: C₁₇H₁₈O₇
• 分子量: 334.326
• InChiKey: WCZBBVLCJJAASE-UHFFFAOYSA-N

物化性质

• 熔点：
  170-172 °C(Solv: acetone (67-64-1))
• 沸点：
  522.9±50.0 °C(Predicted)
• 密度：
  1.283±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  94.4
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  hydroxyphenstatin 在 4-二甲氨基吡啶 、 三甲基氯硅烷 、 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 四氯化碳 、 乙腈 为溶剂， 反应 18.0h， 生成 Phosphoric acid mono-[6-methoxy-2-phosphonooxy-3-(3,4,5-trimethoxy-benzoyl)-phenyl] ester
  参考文献：
  名称：

  Antineoplastic Agents. 443. Synthesis of the Cancer Cell Growth Inhibitor Hydroxyphenstatin and Its Sodium Diphosphate Prodrug

  摘要：

  A structure-activity relationship (SAR) study of the South African willow tree (Combretum caffrum) antineoplastic constituent combretastatin A-4 (3b) led to the discovery of a potent cancer cell growth inhibitor designated phenstatin (5a). This benzophenone derivative of combretastatin A-4 showed remarkable antineoplastic activity, and the benzophenone derivative of combretastatin A-1 was therefore synthesized. The benzophenone, designated hydroxyphenstatin (6a), was synthesized by coupling of a protected bromobenzene and a benzaldehyde to give the benzhydrol with subsequent oxidation to the ketone. Hydroxyphenstatin was converted to the sodium phosphate prodrug (6e) by a dibenzyl phosphite phosphorylation and subsequent benzyl cleavage (6a --> 6d --> 6e). While hydroxyphenstatin (6a) was a potent inhibitor of tubulin polymerization with activity comparable to that of combretastatin A-1 (3a), the phosphorylated derivative (6e) was inactive.

  DOI：

  10.1021/jm000045a
• 作为产物：
  描述：

  (+/-)-2-(2',3'-di[(tert-butyldimethylsilyl)oxy]-4'-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)acetaldehyde 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 反应 0.33h， 以49%的产率得到hydroxyphenstatin
  参考文献：
  名称：

  A Pinacol Rearrangement/Oxidation Synthetic Route to Hydroxyphenstatin¹

  摘要：

  In an attempt to develop biologically active compounds from the inactive trans isomer (3a) of stilbene la, after asymmetric dihydroxylation to optically pure (R,R)-diol 8 the unexpected racemic diphenylacetaldehyde (9) was generated via a Pinacol rearrangement. Several derivatives of diphenylacetaldehyde 9 were synthesized (11-15) and reported. Further reaction of aldehyde 9 during desilylation through autoxidative decarbonylation afforded benzophenone 2b, designated hydroxyphenstatin, a potent antitumor and antimitotic agent. Hydroxyphenstatin showed potent inhibition of the tubulin assembly (IC50 0.82 muM) and exhibited an ED50 of 2.5 mug/mL against the P388 lymphocytic leukemia cell line.

  DOI：

  10.1021/jo000705j

文献信息

• Integrating Metal-Catalyzed C–H and C–O Functionalization To Achieve Sterically Controlled Regioselectivity in Arene Acylation
  作者：Nicholas A. Serratore、Constance B. Anderson、Grant B. Frost、Truong-Giang Hoang、Steven J. Underwood、Philipp M. Gemmel、Melissa A. Hardy、Christopher J. Douglas

  DOI：10.1021/jacs.8b06476

  日期：2018.8.8

  organometallic chemists is the direct functionalization of the bonds most recurrent in organic molecules: C-H, C-C, C-O, and C-N. An even grander challenge is C-C bond formation when both precursors are of this category. Parallel to this is the synthetic goal of achieving reaction selectivity that contrasts with conventional methods. Electrophilic aromatic substitution (EAS) via Friedel-Crafts acylation

  有机金属化学家的一个主要目标是将有机分子中最常见的键直接官能化：CH、CC、CO 和 CN。当两种前体都属于此类时，更大的挑战是 CC 键的形成。与此并行的是实现与传统方法形成对比的反应选择性的合成目标。通过 Friedel-Crafts 酰化的亲电芳香取代 (EAS) 是合成芳基酮的最著名方法，芳基酮是许多药物、农用化学品、香料、染料和其他商品化学品的常见结构基序。然而，只有当所需的酰化位点与反应的电子控制区域选择性一致时，EAS 合成策略才有效。在此，我们报告了空间控制的区域选择性芳烃酰化与水杨酸酯通过铱催化获得明显取代的二苯甲酮。实验和计算数据表明，一种独特的反应机制将 CO 活化和 CH 活化与单一铱催化剂相结合，无需外源氧化剂或碱。我们公开了对芳烃和酯成分的合成范围的广泛探索，最终以简明的合成强效抗癌剂羟基苯司他汀。
• [EN] COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS<br/>[FR] COMPOSITIONS DE BENZOPHÉNONES POLYHYDROXYLÉS ET MÉTHODES DE TRAITEMENT DE TROUBLES NEURODÉGÉNÉRATIFS
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2017106861A1

  公开（公告）日：2017-06-22

  The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.

  本发明涉及聚羟基苯酮类化合物，其在治疗神经退行性、神经学、精神病和认知疾病中有用，特别是那些与HDAC1脱乙酰化酶活性缺乏有关的疾病。
• Hydroxyphenstatin and the prodrugs thereof
  申请人：——

  公开号：US20030220304A1

  公开（公告）日：2003-11-27

  The benzophenone derivative of combretastatin A-1, designated “hydroxyphenstatin”, was synthesized by compiling a protected bromobenzene and a benzaldehyde to form a benzhydrol which was subsequently oxidized to the ketone. Hydroxyphenstatin was converted to a sodium phosphate prodrug by dibenzyl phosphite phosphorylation and subsequent benzyl cleavage: Hydroxyphenstatin and the prodrugs thereof were found to be a potent inhibitor of tubulin polymerization and to demonstrate surprisingly effective anti neoplastic activity against a series of human cancer cells and murine P388 lymphocytic leukemia cells.

  “Hydroxyphenstatin”是一种底物为受保护的溴代苯和苯甲醛的联苯甲醇衍生物，通过氧化反应制得酮。使用二苄基氢氧化磷酸酯磷酸化和苄基裂解的方法将“Hydroxyphenstatin”转化为一种钠盐磷酸酯前药。发现“Hydroxyphenstatin”及其前药能够有效抑制微管聚合，并对一系列人类癌细胞和小鼠P388淋巴细胞白血病具有惊人的抗肿瘤活性。
• Hsp90 FAMILY PROTEIN INHIBITORS
  申请人：Nara Shinji

  公开号：US20090247522A1

  公开（公告）日：2009-10-01

  The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R 1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR 7 R 8 or the like; R 2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R 3 and R 5 , which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R 4 and R 6 , which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.

  本发明提供了Hsp90家族蛋白抑制剂，其包含作为活性成分的苯甲酰化合物，其通式表示为（I）：（其中n表示0到10的整数；R1表示取代或未取代的低烷氧基，取代或未取代的低烷氧羰基，CONR7R8或类似物；R2表示取代或未取代的芳基，取代或未取代的芳香杂环基或类似物；R3和R5，可以相同也可以不同，分别表示氢原子，取代或未取代的低烷基，取代或未取代的低烯基或类似物；R4和R6，可以相同也可以不同，分别表示氢原子，卤素，取代或未取代的低烷基，取代或未取代的芳基或类似物）或其前药，或其药学上可接受的盐。
• Hsp90 family protein inhibitors
  申请人：Nara Shinji

  公开号：US20070032532A1

  公开（公告）日：2007-02-08

  The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R 1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR 7 R 8 or the like; R 2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R 3 and R 5 , which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R 4 and R 6 , which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.

  本发明提供了Hsp90家族蛋白抑制剂，其作为活性成分包括由通式（I）表示的苯甲酰化合物： （其中，n代表0至10的整数；R1代表取代或未取代的较低烷氧基、取代或未取代的较低烷氧羰基、CONR7R8等；R2代表取代或未取代的芳基、取代或未取代的芳香族杂环基等；R3和R5，可以相同也可以不同，每个代表氢原子、取代或未取代的较低烷基、取代或未取代的较低烯基等；R4和R6，可以相同也可以不同，每个代表氢原子、卤素、取代或未取代的较低烷基、取代或未取代的芳基等）或其前药，或所述苯甲酰化合物或其前药的药学上可接受的盐。